Indications

Chronic Kidney Disease (CKD):
Renolife Tablet is indicated for the prevention and treatment of complications resulting from impaired or deficient protein metabolism in patients with chronic kidney disease who are on a restricted protein diet (40 g/day or less in adults). It is generally recommended for patients with a glomerular filtration rate (GFR) below 25 mL/min.

Composition

Each film-coated tablet contains:

Calcium-3-methyl-2-oxo-valerate (α-ketoanalogue of Isoleucine, calcium salt) – 67 mg
Calcium-4-methyl-2-oxo-valerate (α-ketoanalogue of Leucine, calcium salt) – 101 mg
Calcium-2-oxo-3-phenylpropionate (α-ketoanalogue of Phenylalanine, calcium salt) – 68 mg
Calcium-3-methyl-2-oxobutyrate (α-ketoanalogue of Valine, calcium salt) – 86 mg
Calcium-DL-2-hydroxy-4-(methylthio) butyrate (α-hydroxy analogue of Methionine, calcium salt) – 59 mg
L-Lysine Acetate USP (equivalent to Lysine 75 mg) – 105 mg
L-Threonine USP – 53 mg
L-Tryptophan USP – 23 mg
L-Histidine USP (as Histidine Hydrochloride Monohydrate) – 38 mg
L-Tyrosine USP – 30 mg

Pharmacology

Renolife is a nutritional supplement containing essential amino acids and their corresponding ketoanalogues, specifically designed for patients with chronic kidney disease.

These ketoanalogues follow the same metabolic pathways as amino acids and help improve protein metabolism while reducing the nitrogen burden on the kidneys. They provide essential amino acids with minimal amino-nitrogen intake.

The keto- and hydroxy-analogues are converted into their corresponding essential amino acids through transamination, utilizing nitrogen from non-essential amino acids. This process reduces urea formation, promotes nitrogen recycling, and helps maintain nutritional status while minimizing kidney workload.

Dosage & Administration

Unless otherwise prescribed, adults weighing approximately 70 kg should take 4-8 tablets three times daily with meals.
Tablets should be swallowed whole and must not be chewed.
Dietary protein intake should be restricted to 40 g/day or less in adults.
Administration with meals improves absorption and conversion into the corresponding amino acids.
Treatment is usually continued while the patient's GFR remains between 5 and 25 mL/minute.

Drug Interactions

Concomitant use with calcium-containing medicines may increase the risk of hypercalcemia.
If aluminum hydroxide is administered concurrently, dose adjustment of Renolife may be necessary.
Drugs that form insoluble complexes with calcium, including:
- Tetracyclines
- Ciprofloxacin
- Norfloxacin
- Iron-containing products
- Fluoride preparations
- Estramustine
should not be taken simultaneously with Renolife.
A minimum interval of 2 hours should be maintained between Renolife and these medications.
Renolife may increase sensitivity to cardiac glycosides, thereby raising the risk of cardiac arrhythmias.
Serum phosphate levels should be monitored in patients receiving concurrent aluminum hydroxide therapy.

Contraindications

Hypersensitivity to any active ingredient or excipient
Hypercalcemia
Disorders of amino acid metabolism

Side Effects

Very Rare:

Hypercalcemia

If hypercalcemia develops:

Reduce vitamin D intake.
If hypercalcemia persists, reduce the dose of Renolife and other calcium-containing supplements or medications.

Pregnancy & Lactation

Pregnancy: Adequate clinical data regarding the use of amino acid ketoanalogues during pregnancy are not available. Animal studies have not demonstrated direct or indirect harmful effects on pregnancy, fetal development, delivery, or postnatal development. Caution is advised when prescribing during pregnancy.

Lactation: There is currently no clinical experience regarding the use of amino acid ketoanalogues during breastfeeding.